IL-26 and Systemic Lupus Erythematosus

Terminated

• Conditions: Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling

• Registration Number: NCT01889641
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-06-25
• Study First Submitted QC: 2013-06-27
• Study First Posted: 2013-06-28
• Study Start: 2014-02
• Primary Completion: 2015-04
• Study Completion: 2015-04
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-07
• Last Update Posted: 2017-09-08

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• diagnostic of Lupus according to ACR criteria ( four criteria are necessary)
• age > 18 years old

Exclusion Criteria

• treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects	2 years

Trial Locations

Locations (1)

Les Hôpitaux Universitaires de Strasbourg; 🇫🇷 Strasbourg, Bas Rhin, France